PTCISB/08a (08-03 )
Approved for use through 97/31/2006, ONE 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

Application Number

Filing Date

STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)				First I	First Named Inventor Gabrizova							
				Art U	Art Unit							
( NOT TOP SUDMISSION UNder 37 CFR 1.99)					Examiner Name							
					Attorney Docket Number		er	MHOLP-004-US				
										Remove		
					U.S.I	PATENTS				Kemove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Patentee or Applicant of cited Document			Releva		Lines where ges or Relev	
	1	4774093		1988-0	9-27	Provonch	90, et a	al.				
	2	5158772		1992-1	0-27	Davis, Wa	itor B.					
If you wish	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the A	dd button.		Add		
_			U.S.P	ATENT	APPLIC	CATION P	UBLK	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant			Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1											
If you wish	h to a	l dd additional U.S. Publ	ished Ap	plication	n citation	ı n informati	on ple	ase click the Add	i button	Add		_
				FORE	GN PAT	ENT DOC	UME	NTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	n /	Name of Patentee Applicant of cited Document	or v		or Relevant	
	1	0875244	EP			1998-11-0		Ciba Specially Chemicals Holding	Inc.			
	2	9403500	wo			1994-02-1		Consiglio Nazional Delle Ricerche, et a				

	Application Number		
INFORMATION DIGGS COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Gabr	zova
(Not for submission under 37 CFR 1.99)	Art Unit		
(·,	Examiner Name		
	Attorney Docket Numb	er	MHOL.P-004-US

	3	02085	5950	wo		2002-10-31	Gabrizova, Leona		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (block, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and or country where published.						Τs		
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								

See find. Codes of USPTO Patent Documents at sever\_USPTO\_CDX or MEPP 66164. Texter office that seased the document, by the lu-cleider code (WIPO Standard S13.). For Laplanese patent fourments, the inclusion of the parent for the Empartor many precision is sense; internet of the patent fourment. If which office the Coursent by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. Special is to place a check mark there if Empirical Insurations in statistics.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date Filing Date Filing Date Filing Date Filing Date First Number I Medicary Gatherova Art Unit Examiner Name Attorney Docket Number I Medicary Old-US

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97	and 1.36 to make the appropriate selection	1(5):

That each item of information contained in the information disclosure statement was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(a/1).

# ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/s/	Date (YYYY-MM-DD)	2006-06-27
Name/Print	Carl Oppedahl	Registration Number	32746

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.